This article is more than 5 years old. Information may no longer be current.

VIDEO: Sparsentan shows nephroprotective potential for treatment of primary focal segmental glomerulosclerosis

Issue: December 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — At ASN Kidney Week 2018, Howard Trachtman, MD, director of the division of pediatric nephrology at NYU Langone Health, provided an update on the DUET Trial of sparsentan, a dual angiotensin and endothelin receptor antagonist for primary focal segmental glomerulosclerosis.

“The key take-home message is that this maybe very well turn out to be a drug that will replace the angiotensin-receptor blockers alone because in a single pill you will have two complementary actions that will be synergistic to reduce proteinuria with hopefully the same safety profile that nephrologists have encountered when they use angiotensin-receptor blockers to treat proteinuric patients,” he said.